{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:15Z","timestamp":1757618115257,"version":"3.44.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014804","name":"Neurofibromatosis Therapeutic Acceleration Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014804","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","award":["2023-01-006"],"award-info":[{"award-number":["2023-01-006"]}],"id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cutaneous neurofibromas (cNFs) are the hallmark of the tumor-predisposition syndrome neurofibromatosis 1 (NF1). While cNFs are always benign, they markedly decrease quality of life in individuals with NF1. Understanding the differences between cNFs and the skin is essential for developing treatments for cNFs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We collected 15 cNFs from four NF1 individuals and used mass spectrometry to compare the tumor tissue with the skin overlying each tumor. Data were analyzed based on Gene Ontology (GO) terms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The expression patterns of the Schwann cell marker S100B and several keratins confirmed successful dissection of cNF tissue from the overlying skin. Hierarchical clustering showed extensive overlap between the tumor and skin samples in three out of four individuals, suggesting high overall similarity between the two tissue types. Based on the analysis of the GO terms, cNFs were associated with decreased expression of proteins related to cell proliferation, extracellular matrix remodeling, angiogenesis and cellular metabolism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The cNFs are relatively quiescent, consistent with their benign nature and limited growth potential. The development of pharmacological therapy for cNFs requires overcoming the high similarity between cNFs and the overlying skin. The present dataset can serve as a resource for future research on cNFs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-03055-9","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T08:06:28Z","timestamp":1747728388000},"page":"286-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-2980","authenticated-orcid":false,"given":"Roope A.","family":"Kallionp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eija","family":"Martikkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Haapaniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna-Maria","family":"Karppinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilvi","family":"Riihil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Rokka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilmo","family":"Leivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taina","family":"Pihlajaniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-1430","authenticated-orcid":false,"given":"Sirkku","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-4167","authenticated-orcid":false,"given":"Juha","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"3055_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3:17004.","journal-title":"Nat Rev Dis Prim"},{"key":"3055_CR2","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.ajpath.2010.12.056","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol. 2011;178:1932\u20139.","journal-title":"Am J Pathol"},{"key":"3055_CR3","first-page":"305","volume":"53","author":"DF Easton","year":"1993","unstructured":"Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53:305\u201313.","journal-title":"Am J Hum Genet"},{"key":"3055_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1542\/peds.105.3.608","volume":"105","author":"K DeBella","year":"2000","unstructured":"DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105:608\u201314.","journal-title":"Pediatrics"},{"key":"3055_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000327379","volume":"222","author":"TA Duong","year":"2011","unstructured":"Duong TA, Bastuji-Garin S, Valeyrie-Allanore L, Sbidian E, Ferkal S, Wolkenstein P. Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients. Dermatology. 2011;222:269\u201373.","journal-title":"Dermatology"},{"key":"3055_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0772-z","volume":"13","author":"A Cannon","year":"2018","unstructured":"Cannon A, Chen M-J, Li P, Boyd KP, Theos A, Redden DT, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis. 2018;13:31.","journal-title":"Orphanet J Rare Dis"},{"key":"3055_CR7","doi-asserted-by":"crossref","unstructured":"Morris SM, Gupta A, Kim S, Foraker RE, Gutmann DH, Payne PRO. Predictive Modeling for Clinical Features Associated with Neurofibromatosis Type 1. Neurol Clin Pract. 2021;11:497\u2013505.","DOI":"10.1212\/CPJ.0000000000001089"},{"key":"3055_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","volume":"91","author":"N Ortonne","year":"2018","unstructured":"Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, et al. Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology. 2018;91:S5\u201313.","journal-title":"Neurology"},{"key":"3055_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jid.2023.01.043","volume":"143","author":"SD Rhodes","year":"2023","unstructured":"Rhodes SD, McCormick F, Cagan RL, Bakker A, Staedtke V, Ly I, et al. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights. J Investig Dermatol. 2023;143:1358\u201368.","journal-title":"J Investig Dermatol"},{"key":"3055_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2023.06.003","volume":"261","author":"F Coulpier","year":"2023","unstructured":"Coulpier F, Pulh P, Oubrou L, Naudet J, Fertitta L, Gregoire J-M, et al. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice. Transl Res. 2023;261:16\u201327.","journal-title":"Transl Res"},{"key":"3055_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000187594","volume":"218","author":"Y Kodra","year":"2009","unstructured":"Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1: A survey of 129 Italian patients. Dermatology. 2009;218:215\u201320.","journal-title":"Dermatology"},{"key":"3055_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000337548","volume":"224","author":"S Granstr\u00f6m","year":"2012","unstructured":"Granstr\u00f6m S, Langenbruch A, Augustin M, Mautner V-F. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology. 2012;224:160\u20137.","journal-title":"Dermatology"},{"key":"3055_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1265-4","volume":"14","author":"M Guiraud","year":"2019","unstructured":"Guiraud M, Bouroubi A, Beauchamp R, Bocquet A, Gr\u00e9goire J-M, Rauly-Lestienne I, et al. Cutaneous neurofibromas: patients\u2019 medical burden, current management and therapeutic expectations: results from an online European patient community survey. Orphanet J Rare Dis. 2019;14:286.","journal-title":"Orphanet J Rare Dis"},{"key":"3055_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2077","volume":"11","author":"J Fleming","year":"2023","unstructured":"Fleming J, Morgan O, Wong C, Schlub TE, Berman Y. Characterization of health concerns in people with neurofibromatosis type 1. Mol Genet Genom Med. 2023;11:e2077.","journal-title":"Mol Genet Genom Med"},{"key":"3055_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104386","volume":"65","author":"S Peltonen","year":"2022","unstructured":"Peltonen S, Jannic A, Wolkenstein P. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience. Eur J Med Genet. 2022;65:104386.","journal-title":"Eur J Med Genet"},{"key":"3055_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jid.2023.01.041","volume":"143","author":"I Ly","year":"2023","unstructured":"Ly I, Romo CG, Gottesman S, Kelly KM, Kornacki D, York Z, et al. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas. J Investig Dermatol. 2023;143:1388\u201396.","journal-title":"J Investig Dermatol"},{"key":"3055_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.2134734","volume":"249","author":"MR Wallace","year":"1990","unstructured":"Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181\u20136.","journal-title":"Science"},{"key":"3055_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","volume":"62","author":"G Xu","year":"1990","unstructured":"Xu G, O\u2019Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599\u2013608.","journal-title":"Cell"},{"key":"3055_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/jmg.26.11.704","volume":"26","author":"SM Huson","year":"1989","unstructured":"Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989;26:704\u201311.","journal-title":"J Med Genet"},{"key":"3055_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/gim.2017.215","volume":"20","author":"RA Kallionp\u00e4\u00e4","year":"2018","unstructured":"Kallionp\u00e4\u00e4 RA, Uusitalo E, Lepp\u00e4virta J, P\u00f6yh\u00f6nen M, Peltonen S, Peltonen J. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med. 2018;20:1082\u20136.","journal-title":"Genet Med"},{"key":"3055_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:671\u201382.","journal-title":"Genet Med"},{"key":"3055_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506\u201313.","journal-title":"Genet Med"},{"key":"3055_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327\u201332.","journal-title":"Am J Med Genet A"},{"key":"3055_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108:193\u20138.","journal-title":"Br J Cancer"},{"key":"3055_CR25","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, P\u00f6yh\u00f6nen M, Lepp\u00e4virta J, Yl\u00e4-Outinen H, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016;34:1978\u201386.","journal-title":"J Clin Oncol"},{"key":"3055_CR26","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1093\/hmg\/9.20.3055","volume":"9","author":"E Serra","year":"2000","unstructured":"Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet. 2000;9:3055\u201364.","journal-title":"Hum Mol Genet"},{"key":"3055_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/humu.20389","volume":"27","author":"O Maertens","year":"2006","unstructured":"Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat. 2006;27:1030\u201340.","journal-title":"Hum Mutat"},{"key":"3055_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1749-6632.1986.tb48079.x","volume":"486","author":"J Peltonen","year":"1986","unstructured":"Peltonen J, Penttinen R, Larjava H, Aho HJ. Collagens in neurofibromas and neurofibroma cell cultures. Ann N. Y Acad Sci. 1986;486:260\u201370.","journal-title":"Ann N. Y Acad Sci"},{"key":"3055_CR29","first-page":"760","volume":"59","author":"J Peltonen","year":"1988","unstructured":"Peltonen J, Jaakkola S, Lebwohl M, Renvall S, Risteli L, Virtanen I, et al. Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab Investig. 1988;59:760\u201371.","journal-title":"Lab Investig"},{"key":"3055_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000517011","volume":"238","author":"RA Kallionp\u00e4\u00e4","year":"2022","unstructured":"Kallionp\u00e4\u00e4 RA, Ahramo K, Martikkala E, Fazeli E, Haapaniemi P, Rokka A, et al. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1. Dermatology. 2022;238:329\u201339.","journal-title":"Dermatology"},{"key":"3055_CR31","doi-asserted-by":"publisher","first-page":"82037","DOI":"10.18632\/oncotarget.18301","volume":"8","author":"KB Haworth","year":"2017","unstructured":"Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017;8:82037\u201348.","journal-title":"Oncotarget"},{"key":"3055_CR32","doi-asserted-by":"crossref","unstructured":"Banerjee J, Allaway RJ, Taroni JN, Baker A, Zhang X, Moon CI, et al. Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1. Genes (Basel). 2020;11:226.","DOI":"10.3390\/genes11020226"},{"key":"3055_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100285","volume":"104","author":"RA Kallionp\u00e4\u00e4","year":"2024","unstructured":"Kallionp\u00e4\u00e4 RA, Peltonen S, Le KM, Martikkala E, J\u00e4\u00e4skel\u00e4inen M, Fazeli E, et al. Characterization of immune cell populations of cutaneous neurofibromas in neurofibromatosis 1. Lab Investig. 2024;104:100285.","journal-title":"Lab Investig"},{"key":"3055_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1172\/JCI114148","volume":"84","author":"S Jaakkola","year":"1989","unstructured":"Jaakkola S, Peltonen J, Riccardi V, Chu ML, Uitto J. Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures. J Clin Investig. 1989;84:253\u201361.","journal-title":"J Clin Investig"},{"key":"3055_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-020-01103-4","volume":"9","author":"J-P Brosseau","year":"2021","unstructured":"Brosseau J-P, Sathe AA, Wang Y, Nguyen T, Glass DA, Xing C, et al. Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta Neuropathol Commun. 2021;9:11.","journal-title":"Acta Neuropathol Commun"},{"key":"3055_CR36","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1172\/JCI19195","volume":"112","author":"Y Feng-Chun","year":"2003","unstructured":"Feng-Chun Y, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+\/\u2013 mast cells. J Clin Investig. 2003;112:1851\u201361.","journal-title":"J Clin Investig"},{"key":"3055_CR37","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/hmg\/ddl165","volume":"15","author":"FC Yang","year":"2006","unstructured":"Yang FC, Chen S, Clegg T, Li X, Morgan T, Estwick SA, et al. Nf1+\/- mast cells induce neurofibroma like phenotypes through secreted TGF-\u03b2 signaling. Hum Mol Genet. 2006;15:2421\u201337.","journal-title":"Hum Mol Genet"},{"key":"3055_CR38","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2353\/ajpath.2010.100369","volume":"177","author":"S Chen","year":"2010","unstructured":"Chen S, Burgin S, McDaniel A, Li X, Yuan J, Chen M, et al. Nf1-\/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. Am J Pathol. 2010;177:3125\u201332.","journal-title":"Am J Pathol"},{"key":"3055_CR39","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1172\/JCI99424","volume":"128","author":"CP Liao","year":"2018","unstructured":"Liao CP, Booker RC, Brosseau JP, Chen Z, Mo J, Tchegnon E, et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Investig. 2018;128:2848\u201361.","journal-title":"J Clin Investig"},{"key":"3055_CR40","doi-asserted-by":"crossref","unstructured":"Fletcher JS, Wu J, Jessen WJ, Pundavela J, Miller JA, Dombi E, et al. Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI insight. 2019;4:e98601.","DOI":"10.1172\/jci.insight.98601"},{"key":"3055_CR41","first-page":"4713","volume":"35","author":"RE Friedrich","year":"2015","unstructured":"Friedrich RE, Naber U, Glatzel M, Hagel C. Vessel and mast cell densities in sporadic and syndrome-associated peripheral nerve sheath tumors. Anticancer Res. 2015;35:4713\u201322.","journal-title":"Anticancer Res"},{"key":"3055_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"National Institutes of Health Consensus Development Conference.","year":"1988","unstructured":"National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45:575\u20138.","journal-title":"Arch Neurol"},{"key":"3055_CR43","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/acs.jproteome.5b00981","volume":"15","author":"C Lazar","year":"2016","unstructured":"Lazar C, Gatto L, Ferro M, Bruley C, Burger T. Accounting for the Multiple Natures of Missing Values in Label-Free Quantitative Proteomics Data Sets to Compare Imputation Strategies. J Proteome Res. 2016;15:1116\u201325.","journal-title":"J Proteome Res"},{"key":"3055_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"3055_CR45","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","volume":"49","author":"Gene Ontology Consortium.","year":"2021","unstructured":"Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 2021;49:D325\u201334.","journal-title":"Nucleic Acids Res"},{"key":"3055_CR46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65392-8","volume":"154","author":"R Valtola","year":"1999","unstructured":"Valtola R, Salven P, Heikkil\u00e4 P, Taipale J, Joensuu H, Rehn M, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381\u201390.","journal-title":"Am J Pathol"},{"key":"3055_CR47","doi-asserted-by":"crossref","unstructured":"Jiang C, Kumar A, Yu Z, Shipman T, Wang Y, McKay RM, et al. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. J Clin Investig. 2023;133:e168227.","DOI":"10.1172\/JCI168227"},{"key":"3055_CR48","first-page":"487","volume":"62","author":"J Peltonen","year":"1990","unstructured":"Peltonen J, Jaakkola S, Hsiao LL, Timpl R, Chu ML, Uitto J. Type VI collagen. In situ hybridizations and immunohistochemistry reveal abundant mRNA and protein levels in human neurofibroma, schwannoma and normal peripheral nerve tissues. Lab Investig. 1990;62:487\u201392.","journal-title":"Lab Investig"},{"key":"3055_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jid.2023.03.1688","volume":"144","author":"W-N Wang","year":"2024","unstructured":"Wang W-N, Koguchi-Yoshioka H, Nimura K, Watanabe R, Tanemura A, Fujimoto M, et al. Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1. J Investig Dermatol. 2024;144:133\u2013141.e4.","journal-title":"J Investig Dermatol"},{"key":"3055_CR50","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbagen.2015.09.007","volume":"1850","author":"A Walia","year":"2015","unstructured":"Walia A, Yang JF, Huang Y-H, Rosenblatt MI, Chang J-H, Azar DT. Endostatin\u2019s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 2015;1850:2422\u201338.","journal-title":"Biochim Biophys Acta"},{"key":"3055_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2020.100023","volume":"6\u20137","author":"S Bretaud","year":"2020","unstructured":"Bretaud S, Guillon E, Karppinen S-M, Pihlajaniemi T, Ruggiero F. Collagen XV, a multifaceted multiplexin present across tissues and species. Matrix Biol Plus. 2020;6\u20137:100023.","journal-title":"Matrix Biol Plus"},{"key":"3055_CR52","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, et al. The development of cutaneous neurofibromas. Am J Pathol. 2011;178:500\u20135.","journal-title":"Am J Pathol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03055-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:58:50Z","timestamp":1757177930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8,24]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03055-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Hospital District of Southwest Finland (131\/1803\/2017), and Turku University Hospital. All participants provided their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}